Krazati

adagrasib

Approval

ApplicationNDA 216340
Approval dateDec 12, 2022
Approval year2022
SponsorBristol

FDA-approved use

To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Krazati: